Nevertheless, in the Justification for the Use of Statins in Primary Prevention study (24), the use of 20 mg of rosuvastatin in patients with CRP ≥ 2.0 mg/dL reduced the CRP levels by 37% and the composite of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from cardiovascular causes by 46%. This evidence concerns the gene CRP and myocardial infarction.